Clinical Trial Update: To Evaluate the Response to Glucagon During Hypoglycemia [Phase 1]

View source ↗

Summary

AstraZeneca completed a Phase 1 trial evaluating the body's response to glucagon during hypoglycemia in people with Type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GLUCAGON (GLUCAGON)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 1 | Status: COMPLETED